Brief: ExoPTEN Preclinical Study Demonstrates Significant Potential for Enhancing Motor Function, Blood Flow, and Spinal Cord Injury Recovery
14/03/2025 20:13
March 14 (Reuters) - Nurexone Biologic Inc NRX.V: EXOPTEN PRECLINICAL STUDY DEMONSTRATES SIGNIFICANT POTENTIAL FOR ENHANCING MOTOR FUNCTION, BLOOD FLOW, AND SPINAL CORD INJURY RECOVERY Source text: ID:nGNX6Cr40q Further company coverage: NRX.V ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nurexone Biologic
See all newsBrief: Nurexone Announces Binding MoU With Made Scientific For U.S. Gmp Manufacturing And Commercial Supply Partnership
Brief: Corporate Updates – Nurexone Appoints Mr. David Stolick To The Board Of Directors
Brief: Exo-Top, Nurexone’S Wholly Owned U.S. Subsidiary, Enters Into Binding MoU For Naïve Exosome Distribution In Mexico
Brief: Nurexone Biologic’S U.S. Subsidiary Exo-Top And Florida-Based Bioxtek Sign Strategic Loi For Exosome Manufacturing And Commercialization
Brief: Nurexone Strengthens U.S. Manufacturing Strategy Through Exo-Top Sublicense Agreement